Cumberland Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 5/6

Cumberland Pharmaceuticals possède un total de capitaux propres de $24.5M et une dette totale de $16.1M, ce qui porte son ratio d'endettement à 65.8%. Son actif total et son passif total sont $76.7M et de $52.3M.

Informations clés

65.8%

Ratio d'endettement

US$16.09m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$17.46m
Fonds propres	US$24.47m
Total du passif	US$52.28m
Total des actifs	US$76.75m

Mises à jour récentes de la santé financière

Recent updates

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Nov 04

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Mar 07

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

Jan 09

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Oct 02

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Aug 10

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Mar 18

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Nov 02

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Jul 20

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Apr 15

Checking In On Cumberland Pharmaceuticals

Jan 04

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Nov 09

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Apr 21

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

Feb 13

One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts

Nov 19

Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CPIX ( $35.2M ) dépassent ses passifs à court terme ( $31.1M ).

Passif à long terme: Les actifs à court terme de CPIX ( $35.2M ) dépassent ses passifs à long terme ( $21.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: CPIX dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de CPIX est passé de 38.7% à 65.8% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CPIX dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CPIX dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de croître à un taux historique de 19.7 % chaque année

Cumberland Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Recent updates

Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)

Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to Ketorolac

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023)

Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024

Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million.

New minor risk - Share price stability

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022)

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024

Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023

Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age

New minor risk - Share price stability

Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022)

Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023

Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs

Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis

U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor

First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022)

Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?

Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021)

Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors

Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021)

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021)

Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)

Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors

Cumberland Pharmaceuticals Inc. Announces Executive Changes

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?

Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022

Now 22% undervalued

Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million.

Checking In On Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor®

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020)

Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020)

Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) dropped from Russell Microcap Growth Index

Cumberland Pharmaceuticals Inc. Releases a Series of Case Reports Describing the Effectiveness of Vibativ® (Telavancin) in Treating Secondary Bacterial Infections in COVID-19 Patients

Consensus EPS estimates increase to -US$0.18

We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation

Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.43 loss per share (vs US$0.23 loss in FY 2019)

Revenue beats expectations

Cumberland Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 09, 2021

Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?

New 90-day high: US$3.31

New 90-day high: US$3.22

Analysts update estimates